glp-1 treatment nyc 3 Takeaways from the Landmark Oral 'Switch' Trial for Obesity Care GLP-1 Therapy in NYC by

A vicious circle

It also improves insulin sensitivity, dyslipidemia, and prolactinemia

This is metabolic adaptation, and it is not a sign that your medication has stopped working

Differentiating medication-linked NAION from other causes of sudden vision loss is crucial

In our study, we examine: Trends in GLP-1 prevalence, adherence data, and potential obstacles to continued use Impacts on mortality among individuals taking these drugs Implications for assessing metabolic risk and the crucial role electronic health records (EHRs) will play Key results GLP-1s may drive 0.2%0.5% annual mortality improvement, realized over a 20-year period